Compounds > gallium maltolate
Page last updated: 2024-12-11

gallium maltolate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gallium maltolate: has antineoplastic activity [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9846339
MeSH IDM0501003

Synonyms (11)

Synonym
gallium maltolate
gallium, tris(3-(hydroxy-.kappa.o)-2-methyl-4h-pyran-4-onato-.kappa.o4)-, (oc-6-21)-
108560-70-9
gallium maltolate [inci]
17LEI49C2G ,
ASYYOZSDALANRF-UHFFFAOYSA-K
DB05420
gallium tris(2-methyl-4-oxo-4h-pyran-3-olate)
B2699-054157
gallium;2-methyl-4-oxopyran-3-olate
3-bis[(2-methyl-4-oxopyran-3-yl)oxy]gallanyloxy-2-methylpyran-4-one

Research Excerpts

Actions

ExcerptReferenceRelevance
"Gallium maltolate produced an increase in intracellular reactive oxygen species (ROS) within 2 h of incubation with cells; this effect could be blocked by mitoquinone, a mitochondria-targeted antioxidant."( Development of gallium compounds for treatment of lymphoma: gallium maltolate, a novel hydroxypyrone gallium compound, induces apoptosis and circumvents lymphoma cell resistance to gallium nitrate.
Chitambar, CR; Purpi, DP; Wereley, JP; Woodliff, J; Yang, M, 2007)		1.3

Pharmacokinetics

ExcerptReferenceRelevance
" Mean elimination half-life was 32."( Pharmacokinetics of an orally administered methylcellulose formulation of gallium maltolate in neonatal foals.
Arnold, CE; Bernstein, LR; Chaffin, MK; Cohen, ND; Fajt, V; Martens, RJ; O'Conor, M; Taylor, RJ, 2010)		0.59
" Pharmacokinetic models were selected on the basis of the Akaike information criterion and visual analysis of plots of residuals."( Pharmacokinetics of gallium maltolate after intragastric administration in adult horses.
Arnold, C; Bernstein, LR; Chaffin, MK; Cohen, N; Fajt, VR; Taylor, RJ, 2010)		0.68
" Noncompartmental analysis was used to determine individual pharmacokinetic parameters."( Pharmacokinetics of gallium maltolate after intragastric administration in adult horses.
Arnold, C; Bernstein, LR; Chaffin, MK; Cohen, N; Fajt, VR; Taylor, RJ, 2010)		0.68
"03]; but half-life (59."( Pharmacokinetics of gallium maltolate in Lawsonia intracellularis-infected and uninfected rabbits.
Alcorn, J; Allen, AL; Ball, KR; Bernstein, LR; Clark, CR; Dowling, PM; Gebhart, CJ; Hamilton, DL; Mapes, S; Pusterla, N; Sampieri, F; Thompson, J; Vannucci, FA, 2014)		0.73

Bioavailability

Gallium maltolate (GaM) provides significant gallium bioavailability to people and mice following oral administration and to neonatal foals following intragastric administration. Previous studies indicate that oral Gallium Maltolate would provide a higher bioavailability than oral Ga salts.

ExcerptReferenceRelevance
" Gallium maltolate (GaM) provides significant gallium bioavailability to people and mice following oral administration and to neonatal foals following intragastric administration."( Pharmacokinetics of an orally administered methylcellulose formulation of gallium maltolate in neonatal foals.
Arnold, CE; Bernstein, LR; Chaffin, MK; Cohen, ND; Fajt, V; Martens, RJ; O'Conor, M; Taylor, RJ, 2010)		1.5
"Further studies are necessary to determine the bioavailability of GaM after intragastric administration in adult horses."( Pharmacokinetics of gallium maltolate after intragastric administration in adult horses.
Arnold, C; Bernstein, LR; Chaffin, MK; Cohen, N; Fajt, VR; Taylor, RJ, 2010)		0.68
" Previous studies indicate that oral gallium maltolate (GaM) would provide a higher bioavailability than oral Ga salts."( Reduction in absorption of gallium maltolate in adult horses following oral administration with food: chemistry and pharmacokinetics.
Dean, A; Di Marco, V; Marton, D; Pepe, M; Pollina, GF, 2013)		0.96

Dosage Studied

ExcerptRelevanceReference
" In conclusion, although infection reduces IT [Ga] and [Fe], a 48 h GaM dosing interval is appropriate for multidose studies in EPE rabbits."( Pharmacokinetics of gallium maltolate in Lawsonia intracellularis-infected and uninfected rabbits.
Alcorn, J; Allen, AL; Ball, KR; Bernstein, LR; Clark, CR; Dowling, PM; Gebhart, CJ; Hamilton, DL; Mapes, S; Pusterla, N; Sampieri, F; Thompson, J; Vannucci, FA, 2014)		0.73
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (10.00)29.6817
2010's22 (73.33)24.3611
2020's5 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.23

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.23 (24.57)
Research Supply Index3.58 (2.92)
Research Growth Index4.78 (4.65)
Search Engine Demand Index50.99 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.23)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.06%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (6.06%)4.05%
Observational0 (0.00%)0.25%
Other29 (87.88%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
oxyquinoline
Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.		2.1110monohydroxyquinolineantibacterial agent;
antifungal agrochemical;
antiseptic drug;
iron chelator
gentamicin
Gentamicins: A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS.		7.3110
maltol
maltol: found in bark of young larch trees; isolated from Passiflora incarnata; possesses depressant properties in mice; potentiates hexobarbital-induced narcosis & inhibits spontaneous motor activity; structure		2.11104-pyranonesmetabolite
pyrazines
Pyrazines: A heterocyclic aromatic organic compound with the chemical formula C4H4N2.. pyrazine : A diazine that is benzene in which the carbon atoms at positions 1 and 4 have been replaced by nitrogen atoms.		2.0510diazine;
pyrazines		Daphnia magna metabolite
gallium nitrate
gallium nitrate: RN given refers to parent cpd		2.9840
bortezomib
[no description available]		2.0510amino acid amide;
L-phenylalanine derivative;
pyrazines		antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor
alpha-chymotrypsin
Chymotrypsin: A serine endopeptidase secreted by the pancreas as its zymogen, CHYMOTRYPSINOGEN and carried in the pancreatic juice to the duodenum where it is activated by TRYPSIN. It selectively cleaves aromatic amino acids on the carboxyl side.		2.0510
gallium
Gallium: A rare, metallic element designated by the symbol, Ga, atomic number 31, and atomic weight 69.72.. gallium atom : A metallic element predicted as eka-aluminium by Mendeleev in 1870 and discovered by Paul-Emile Lecoq de Boisbaudran in 1875. Named in honour of France (Latin Gallia) and perhaps also from the Latin gallus cock, a translation of Lecoq.		3.3160boron group element atom
methylcellulose
Methylcellulose: Methylester of cellulose. Methylcellulose is used as an emulsifying and suspending agent in cosmetics, pharmaceutics and the chemical industry. It is used therapeutically as a bulk laxative.		7.0510
rifampin
Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)		2.2510cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion		angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor
ConditionIndicatedRelationship StrengthStudiesTrials
ER-Negative PR-Negative HER2-Negative Breast Cancer
[description not available]		02.610
Triple Negative Breast Neoplasms
Breast neoplasms that do not express ESTROGEN RECEPTORS; PROGESTERONE RECEPTORS; and do not overexpress the NEU RECEPTOR/HER-2 PROTO-ONCOGENE PROTEIN.		02.610
Bacterial Pneumonia
[description not available]		02.7830
Equine Diseases
[description not available]		03.4870
Pneumonia, Bacterial
Inflammation of the lung parenchyma that is caused by bacterial infections.		02.7830
Infections, Staphylococcal
[description not available]		02.6920
Injuries, Leg
[description not available]		02.2510
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.6920
Osteomyelitis
INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.		07.3110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		03.2250
Astrocytoma, Grade IV
[description not available]		02.1710
Glioblastoma
A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.		07.1710
Frambesia
[description not available]		02.2110
Yaws
A systemic non-venereal infection of the tropics caused by TREPONEMA PALLIDUM subspecies pertenue.		07.2110
E coli Infections
[description not available]		02.0810
Cystitis
Inflammation of the URINARY BLADDER, either from bacterial or non-bacterial causes. Cystitis is usually associated with painful urination (dysuria), increased frequency, urgency, and suprapubic pain.		02.0810
Escherichia coli Infections
Infections with bacteria of the species ESCHERICHIA COLI.		02.0810
Urinary Tract Infections
Inflammatory responses of the epithelium of the URINARY TRACT to microbial invasions. They are often bacterial infections with associated BACTERIURIA and PYURIA.		02.0810
Bilophila Infections
[description not available]		02.520
Corynebacterium Infections
Infections with bacteria of the genus CORYNEBACTERIUM.		02.110
Carcinogenesis
The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.		02.1110
Cancer of Skin
[description not available]		02.1110
Cutaneous T-Cell Lymphoma
[description not available]		07.1110
Skin Neoplasms
Tumors or cancer of the SKIN.		02.1110
Lymphoma, T-Cell, Cutaneous
A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.		02.1110
Infections, Pseudomonas
[description not available]		02.0510
Burns
Injuries to tissues caused by contact with heat, steam, chemicals (BURNS, CHEMICAL), electricity (BURNS, ELECTRIC), or the like.		02.0510
Pseudomonas Infections
Infections with bacteria of the genus PSEUDOMONAS.		02.0510
Infection, Postoperative Wound
[description not available]		02.0510
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated
[description not available]		02.0510
Lymphoma, Mantle-Cell
A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).		02.0510
Actinomycetales Infections
Infections with bacteria of the order ACTINOMYCETALES.		02.7530
Bone Diseases
Diseases of BONES.		02.0510
Hepatocellular Carcinoma
[description not available]		07.0610
Cancer of Liver
[description not available]		02.0610
Carcinoma, Hepatocellular
A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.		02.0610
Liver Neoplasms
Tumors or cancer of the LIVER.		02.0610
Chronic Illness
[description not available]		02.0710
Postherpetic Neuralgia
[description not available]		07.0710
Craniofacial Pain
[description not available]		02.0710
Chronic Disease
Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).		02.0710
Facial Pain
Pain in the facial region including orofacial pain and craniofacial pain. Associated conditions include local inflammatory and neoplastic disorders and neuralgic syndromes involving the trigeminal, facial, and glossopharyngeal nerves. Conditions which feature recurrent or persistent facial pain as the primary manifestation of disease are referred to as FACIAL PAIN SYNDROMES.		02.0710
Neuralgia, Postherpetic
Pain in nerves, frequently involving facial SKIN, resulting from the activation the latent varicella-zoster virus (HERPESVIRUS 3, HUMAN). The two forms of the condition preceding the pain are HERPES ZOSTER OTICUS; and HERPES ZOSTER OPHTHALMICUS. Following the healing of the rashes and blisters, the pain sometimes persists.		02.0710
Germinoblastoma
[description not available]		02.0310
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		07.0310